

Elia Sechi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9430702/publications.pdf>

Version: 2024-02-01

67
papers

1,987
citations

361413
20
h-index

289244
40
g-index

69
all docs

69
docs citations

69
times ranked

1605
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposure to TNF inhibitors is rare at MOGAD presentation. Journal of the Neurological Sciences, 2022, 432, 120044.	0.6	7
2	Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Multiple Sclerosis and Related Disorders, 2022, 58, 103424.	2.0	25
3	LG11 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	1.9	48
4	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	1.0	1
5	Rasagiline Withdrawal Syndrome in Parkinson's Disease. Brain Sciences, 2022, 12, 219.	2.3	2
6	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Frontiers in Neurology, 2022, 13, 866824.	2.4	16
7	Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders. Multiple Sclerosis and Related Disorders, 2022, 63, 103827.	2.0	10
8	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	3.0	64
9	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	3.0	7
10	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	3.0	4
11	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 47, 102638.	2.0	20
12	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. Journal of Thoracic Oncology, 2021, 16, 381-394.	1.1	12
13	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 1037-1045.	3.0	3
14	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. Neurology: Clinical Practice, 2021, 11, e601-e611.	1.6	21
15	Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199890.	3.5	15
16	Clinical spectrum of high-titre GAD65 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 645-654.	1.9	84
17	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke, 2021, 52, 645-654.	2.0	9
18	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	9.0	124

#	ARTICLE	IF	CITATIONS
19	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021, 97, e1097-e1109.	1.1	77
20	Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. <i>Frontiers in Neurology</i> , 2021, 12, 673339.	2.4	40
21	HERV-K Modulates the Immune Response in ALS Patients. <i>Microorganisms</i> , 2021, 9, 1784.	3.6	15
22	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.1	25
23	Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2021, 358, 577666.	2.3	3
24	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 384-390.	1.9	55
25	Evaluation and Management of Acute Myelopathy. <i>Seminars in Neurology</i> , 2021, 41, 511-529.	1.4	8
26	Neurochondrin immunoglobulin G “Associated myelopathy” Ataxia syndrome. <i>Journal of the Neurological Sciences</i> , 2021, , 120058.	0.6	2
27	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110487.	1.0	5
28	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110526.	1.0	11
29	Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination. <i>Vaccines</i> , 2021, 9, 1502.	4.4	13
30	Area postrema syndrome in autoimmune GFAP astrocytopathy. <i>Multiple Sclerosis Journal</i> , 2020, 26, 255-256.	3.0	4
31	Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. <i>Journal of Neuroimmunology</i> , 2020, 338, 577110.	2.3	23
32	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101487.	2.0	35
33	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. <i>Clinical Chemistry</i> , 2020, 66, 1496-1509.	3.2	41
34	Unfavorable outcome in highly relapsing MOGAD encephalitis. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117088.	0.6	8
35	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G “Associated Disorder. <i>JAMA Neurology</i> , 2020, 77, 1575.	9.0	52
36	Neurologic autoimmunity and immune checkpoint inhibitors. <i>Neurology</i> , 2020, 95, e2442-e2452.	1.1	94

#	ARTICLE	IF	CITATIONS
37	Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers. <i>Current Rheumatology Reports</i> , 2020, 22, 88.	4.7	12
38	Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?. <i>Journal of the Neurological Sciences</i> , 2020, 413, 116868.	0.6	4
39	Serum neurofilament light chain studies in neurological disorders, hints for interpretation. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116986.	0.6	15
40	FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102283.	2.0	15
41	Diagnostic features of initial demyelinating events associated with serum MOG-IgG. <i>Journal of Neuroimmunology</i> , 2020, 344, 577260.	2.3	0
42	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 488-490.	1.9	54
43	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019, 93, e414-e420.	1.1	26
44	Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential. <i>Journal of Circulating Biomarkers</i> , 2019, 8, 184945441987591.	1.3	4
45	Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. <i>Journal of Neurology</i> , 2019, 266, 1643-1648.	3.6	41
46	Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1293-1296.	1.9	40
47	Diagnosis and Management of Autoimmune Dementia. <i>Current Treatment Options in Neurology</i> , 2019, 21, 11.	1.8	16
48	Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2019, 92, 343-344.	1.1	4
49	Unilateral motor progression in MS. <i>Neurology</i> , 2019, 93, e628-e634.	1.1	22
50	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	9.0	243
51	<i>Mycobacterium avium</i> subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2018, 318, 97-102.	2.3	12
52	Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings. <i>Multiple Sclerosis Journal</i> , 2018, 24, 685-688.	3.0	15
53	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. <i>Lancet Neurology</i> , The, 2018, 17, 498-499.	10.2	2
54	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. <i>Journal of Neurology</i> , 2017, 264, 2420-2430.	3.6	120

#	ARTICLE	IF	CITATIONS
55	Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774242.	1.0	10
56	Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutrition Reviews, 2016, 74, 281-300.	5.8	113
57	Paradoxical Effect of Levetiracetam in Newly Diagnosed Type II Focal Cortical Dysplasia. Clinical Neuropharmacology, 2016, 39, 265-268.	0.7	7
58	Neuralgic amyotrophy mimicking Vernet syndrome. Journal of the Neurological Sciences, 2016, 362, 230-231.	0.6	2
59	Longitudinally Extensive Spinal Cord Lesions Disclosing Occult Systemic Sarcoidosis. JAMA Neurology, 2016, 73, 600.	9.0	0
60	Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia. BMC Neurology, 2015, 15, 256.	1.8	14
61	Clinicopathologic features of folate-deficiency neuropathy. Neurology, 2015, 85, 1090-1091.	1.1	4
62	Teaching Neuro Images : Subacute encephalopathy in a young woman with <i>THTR2</i> gene mutation. Neurology, 2015, 85, e108-9.	1.1	11
63	Restless legs syndrome and cerebrovascular disease. Lancet Neurology, The, 2013, 12, 734.	10.2	3
64	Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up. JIMD Reports, 2012, 9, 67-71.	1.5	11
65	Anatomical variability of the lateral femoral cutaneous nerve: Findings from a surgical series. Clinical Anatomy, 2009, 22, 365-370.	2.7	96
66	Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis. Neurology, 0, , 10.1212/WNL.0000000000200837.	1.1	3
67	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology, 0, 13, .	2.4	84